FDA clears first gene therapy for a rare disorder managed with round-the-clock cornstarch

The FDA granted accelerated approval on 19 August to GENGLYCOS (pariglasgene brecaparvovec-opnr, also called DTX401), an AAV8 gene therapy for glycogen storage disease type Ia (GSDIa) in patients eight years and older [s1]. It is the first FDA-approved treatment aimed at the underlying cause of the disease, rather than at managing its symptoms — and, for its maker Ultragenyx, its first gene-therapy approval and fifth FDA approval overall [s1].

What GSDIa does, and why cornstarch has been the treatment

GSDIa is an ultra-rare genetic disorder — affecting an estimated 1,500 to 2,500 people in the US and 6,000 to 8,000 worldwide in commercially reachable regions [s1] — caused by a deficiency in the enzyme the liver needs to release glucose into the bloodstream during fasting. Left uncorrected, that deficiency produces potentially life-threatening hypoglycemia. For decades, the only management option has been a strict, around-the-clock regimen of raw cornstarch as a slow-release glucose source, which Ultragenyx describes as "crude," producing large glucose swings and pushing many patients into significant hyperglycemia much of the day just to avoid dangerous lows [s1]. "Any missed cornstarch puts patients at risk of severe hypoglycemia, seizures, and even death," said Dr. David Weinstein, described by Ultragenyx as one of the field's leading GSDIa researchers, in the company's approval announcement [s1].

GENGLYCOS is designed to deliver a working copy of the G6Pase gene to liver cells so the body can regulate glucose on its own again, reducing dependence on that cornstarch regimen [s1].

The evidence behind approval — and what "accelerated" means here

The approval rests on the 48-week, randomized, double-blind, placebo-controlled Phase 3 GlucoGene study, which treated 46 participants aged eight and older with a single DTX401 infusion (1.0 × 10¹³ GC/kg) or placebo. In the 44-patient modified intention-to-treat population (20 treated, 24 placebo) analyzed at Week 48, the treated group showed a statistically significant reduction in daily cornstarch requirements (p<0.001) [s1]. At Week 48, placebo participants were allowed to cross over and receive the therapy; follow-up continues through Weeks 96 and 144 [s1].

Because this is an accelerated approval — a pathway that lets FDA authorize a drug based on an intermediate measure (here, cornstarch reduction) rather than a fully established clinical-outcome endpoint — continued approval is contingent on confirming clinical benefit in further study [s1]. Ultragenyx has committed to two years of additional safety and efficacy data from 50 commercially treated patients and 20 comparison patients who sought treatment but could not receive it due to pre-existing anti-AAV8 antibodies, through an expanded disease monitoring program that will track participants for up to ten years [s1].

The safety profile carries real weight

GENGLYCOS's prescribing information lists several serious risks that go beyond a routine infusion drug. It is contraindicated in patients with severe hepatic fibrosis or cirrhosis. Warnings cover hypersensitivity reactions and infusion reactions, including anaphylaxis; immune-mediated hepatotoxicity requiring liver monitoring for at least six months post-infusion; adrenal insufficiency tied to the corticosteroids used to manage the therapy's liver effects, which must be tapered gradually rather than stopped abruptly; and a theoretical tumor risk from AAV vector DNA potentially integrating into the genome, which is now a standard disclosure across AAV gene therapies but not a zero-risk one [s1].

In the Phase 3 trial's primary analysis period, seven serious adverse events occurred, including two cases of anaphylaxis or infusion reaction, two of adrenal insufficiency, two of elevated lactate and one of hypoglycemia. The most common adverse reactions in treated patients, occurring in at least 10%, were elevated liver enzymes (71%), nausea (38%), hypertriglyceridemia (29%), adrenal insufficiency (24%), headache (24%), acne or acneiform dermatitis (19%), constipation (19%), hyperglycemia (14%), Cushingoid features (14%) and anaphylaxis (10%) [s1]. The label also advises against vaccination in the month before infusion, given the immunosuppressive corticosteroid regimen that accompanies treatment, and states GENGLYCOS should not be used during pregnancy [s1].

What comes next for patients

GENGLYCOS will be administered only through a network of "Qualified Treatment Centers" with specific gene-therapy training, and Ultragenyx says the product is manufactured entirely at its own facility in Bedford, Massachusetts [s1]. The company also received a Priority Review Voucher as part of the approval — a separate FDA incentive it can use to speed review of a future drug application or sell to another company [s1]. Ultragenyx has not disclosed a list price in its approval announcement.

The accelerated-approval structure means the real test is still ahead: whether the reduction in cornstarch dependence seen in trial translates, over the ten-year monitoring window, into fewer hypoglycemic emergencies and a durable quality-of-life benefit — the kind of outcome data that FDA is explicitly deferring judgment on for now.

Sources

• Ultragenyx Announces U.S. FDA Approval of GENGLYCOS Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa), Ultragenyx Pharmaceutical Inc., 19 August 2026